Skip to nav Skip to content
Jingsong  Zhang

Jingsong Zhang, MD, PhD

Interim Vice Chair, Department of Genitourinary Oncology

Program: Genitourinary Oncology

Research Program: Molecular Medicine Program

Contact

  • Overview

    Associations

    • Genitourinary Oncology
    • Integrated Mathematical Oncology
    • Molecular Medicine Program
    • Cancer Chemoprevention Research Interest Group
    • Experimental Therapeutics Program
    • Cancer Imaging & Technology Center of Excellence
    • Center of Excellence for Evolutionary Therapy

    Education & Training

    Graduate:

    • University of Southern California, PhD - Pathobiology

    Continuing Education:

    • Memorial Sloan Kettering Cancer Center - Rotations - Medical Oncology

    Board Certification:

      Fellowship:

      • University of Michigan Comprehensive Cancer Center - Hematology-Oncology

      Residency:

      • New York Downtown Hospital - Internal Medicine

      Medical School:

      • Peking Union Medical College - MD
    • Research Interest

      Dr. Zhang’s research focuses on 1) defining and characterizing deregulated pathways with therapeutic relevance in subsets of human cancers, and 2) developing and implementing biomarker-driven therapeutics into patient-based therapeutic trials.He aims to identify the DNA damage repair pathways that metastatic prostate cancers rely on and then assess the therapeutic potential of targeting these pathways. Preliminary data indicates that blocking key proteins in DDR pathways with PARP inhibitor, DNA-PK inhibitor or BRCA1 shRNA sensitized metastatic prostate cancer cells to DNA damaging chemotherapy drugs. The synergistic combinations are being tested in metastatic prostate cancer mouse models.Secondly, Dr. Zhang is evaluating r-H2AX as a prognostic or predictive marker.Unrepaired DNA single strand breaks will be converted to double strand breaks (DSB) during DNA replication, and r-H2AX is a well-known marker for DNA DSB.  High levels of r-H2AX expression in prostate cancers would correlate with diminished DNA repair pathways and therefore high mutation rates.  Dr. Zhang and colleagues will develop a scoring system for r-H2AX expression by immunohistochemistry and correlate that with patients’ clinical outcomes. Based on initial results, the value of r-H2AX can be further evaluated in larger patient cohorts with multi-variant analysis.  Assays also can be developed to detect r-H2AX in circulating tumor cells.

    • Participating Trials

      Clinical Trial 21139
      A Phase IIA Study of Sequential ("first strike, second strike") Therapies, Modeled on Evolutionary Dynamics of Anthropocene Extinctions, for High Risk Metastatic Castration Sensitive Prostate Cancer
      Condition: Genitourinary
      Intervention: Abiraterone acetate (); Apalutamide (); Decapeptyl SR (Triptorelin); Degarelix (); Eligard (Leuprolide); Enzalutamide (Xtandi); Leuprolide (); Relugolix (Orgovyx); Taxotere (docetaxel); Tislelizumab (); Triptorelin (); Zytiga (Abiraterone acetate); docetaxel (); goserelin acetate (Zoladex); prednisone ()
      Status: Open

      Clinical Trial 21559
      A Phase 1/2 Study of EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with Metastatic Castration-Resistant Prostate Cancer
      Condition: Genitourinary
      Intervention: EPI-7386 (); Enzalutamide (Xtandi); Not Applicable ()
      Status: Open

      Clinical Trial 22003
      A Phase II Randomized Study of Sipuleucel-T with or without Continuing New Hormonal Agents (NHA) in Metastatic Prostate Cancer with PSA Progression while on NHA and LHRH Analog
      Condition: Genitourinary
      Intervention: Abiraterone (); Apalutamide (); Enzalutamide (Xtandi); Provenge (Sipuleucel-T); Sipuleucel-T (); prednisone ()
      Status: Open

      Clinical Trial 22297
      Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination with Olaparib or Enzalutamide in Adult Patients with Advanced Solid Tumors
      Condition: Genitourinary
      Intervention: Enzalutamide (Xtandi); NUV-868 (); Olaparib (Lynparza)
      Status: Open

      Clinical Trial 22344
      A Phase I Clinical Trial of an Infusion of Autologous gamma delta T cells Genetically Engineered with a Chimeric Receptor to Target the Prostate Stem Cell Antigen in Patients with Metastatic Castration Resistant Prostate Cancer
      Condition: Genitourinary
      Intervention: MSGV1-PSCA-8T28Z (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
      Status: Open

      If you believe you are eligible for one of these trials or studies, please call
      813-745-6100 or toll-free 1-800-679-0775.

    • Publications

      • Lara PN, Mayerson E, Gertz E, Tangen C, Goldkorn A, van Loan M, Hussain M, Gupta S, Zhang J, Parikh M, Twardowski P, Quinn DI, LeBlanc M, Thompson I, Agarwal N. Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel. Prostate Cancer P D. 2024 Feb. Pubmedid: 38424319.
      • Meng L, Yang Y, Mortazavi A, Zhang J. Emerging Immunotherapy Approaches for Treating Prostate Cancer. Int J Mol Sci. 2023 Sep.24(18). Pubmedid: 37762648. Pmcid: PMC10531627.
      • Abida W, Campbell D, Patnaik A, Bryce AH, Shapiro J, Bambury RM, Zhang J, Burke JM, Castellano D, Font A, Ganju V, Hardy-Bessard AC, McDermott R, Sautois B, Spaeth D, Voog E, Piulats JM, Pintus E, Ryan CJ, Merseburger AS, Daugaard G, Heidenreich A, Fizazi K, Loehr A, Despain D, Simmons AD, Dowson M, Go J, Watkins SP, Chowdhury S. Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study. Eur Urol. 2023 Sep.84(3):321-330. Pubmedid: 37277275. Pmcid: PMC10527050.
      • Li Q, Huang CC, Huang S, Tian Y, Huang J, Bitaraf A, Dong X, Nevalanen MT, Zhang J, Manley BJ, Park JY, Kohli M, Gore EM, Kilari D, Wang L. 5-hydroxymethylcytosine sequencing in plasma cell-free DNA identifies unique epigenomic features in prostate cancer patients resistant to androgen deprivation therapy. medRxiv. 2023 Oct. Pubmedid: 37904926. Pmcid: PMC10615016.
      • Li R, Sexton WJ, Dhillon J, Berglund A, Naidu S, Borjas G, Rose K, Kim Y, Wang X, Conejo-Garcia JR, Jain RK, Poch MA, Spiess PE, Pow-Sang J, Gilbert SM, Zhang J. A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma In Situ of the Bladder. Clin Cancer Res. 2023 Oct.29(19):3875-3881. Pubmedid: 37505486.
      • Chahoud J, Anderson ARA, Zhang J, Brown J, Gatenby RA. Evolutionary Dynamics and Intermittent Therapy for Metastatic Cancers. J Clin Oncol. 2023 Oct.41(28):4469-4471. Pubmedid: 37418680. Pmcid: PMC10553063.
      • Li R, Naidu S, Fan W, Rose K, Huelster H, Grass GD, Vosoughi A, Dhillon J, Kim Y, Gupta S, Jain RK, Zhang J, Zemp L, Yu A, Poch MA, Spiess PE, Pow-Sang J, Gilbert SM, Sexton WJ. Effectiveness of perioperative chemotherapy and radical cystectomy in treating bladder cancer. Urol Oncol. 2023 Nov.41(11):457.e17-457.e24. Pubmedid: 37880002.
      • Loehr A, Hussain A, Patnaik A, Bryce AH, Castellano D, Font A, Shapiro J, Zhang J, Sautois B, Vogelzang NJ, Chatta G, Courtney K, Harzstark A, Ricci F, Despain D, Watkins S, King C, Nguyen M, Simmons AD, Chowdhury S, Abida W. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. Eur Urol. 2023 Mar.83(3):200-209. Pubmedid: 36243543.
      • Soupir AC, Tian Y, Stewart PA, Nunez-Lopez YO, Manley BJ, Pellini B, Bloomer AM, Zhang J, Mo Q, Marchion DC, Liu M, Koomen JM, Siegel EM, Wang L. Detectable Lipidomes and Metabolomes by Different Plasma Exosome Isolation Methods in Healthy Controls and Patients with Advanced Prostate and Lung Cancer. Int J Mol Sci. 2023 Jan.24(3). Pubmedid: 36768152. Pmcid: PMC9916336.
      • Kim JW, McKay RR, Radke MR, Zhao S, Taplin ME, Davis NB, Monk P, Appleman LJ, Lara PN, Vaishampayan UN, Zhang J, Paul AK, Bubley G, Van Allen EM, Unlu S, Huang Y, Loda M, Shapiro GI, Glazer PM, LoRusso PM, Ivy SP, Shyr Y, Swisher EM, Petrylak DP. Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984. J Clin Oncol. 2023 Feb.41(4):871-880. Pubmedid: 36256912. Pmcid: PMC9901975.
      • Gallaher J, Strobl M, West J, Gatenby R, Zhang J, Robertson-Tessi M, Anderson ARA. Intermetastatic and Intrametastatic Heterogeneity Shapes Adaptive Therapy Cycling Dynamics. Cancer Res. 2023 Aug.83(16):2775-2789. Pubmedid: 37205789. Pmcid: PMC10425736.
      • Bibok A, Kis B, Frakes J, Hoffe S, Zhang J, Jain R, Parikh N. Yttrium-90 Radioembolization for Liver-Dominant Metastatic Prostate Cancer: A Case Series. J Vasc Interv Radiol. 2022 Sep.33(9):1061-1065. Pubmedid: 36049841.
      • Aydin AM, Cheriyan SK, Reich R, Hajiran A, Peyton CC, Zemp L, Yu A, Li R, Poch MA, Spiess PE, Jain R, Zhang J, Sexton WJ, Gilbert SM. Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer. Urol Oncol. 2022 Oct.40(10):453.e19-453.e26. Pubmedid: 35811208.
      • Zhang J, Gallaher J, Cunningham JJ, Choi JW, Ionescu F, Chatwal MS, Jain R, Kim Y, Wang L, Brown JS, Anderson AR, Gatenby RA. A Phase 1b Adaptive Androgen Deprivation Therapy Trial in Metastatic Castration Sensitive Prostate Cancer. Cancers (Basel). 2022 Oct.14(21). Pubmedid: 36358643. Pmcid: PMC9656891.
      • Chakiryan NH, Gore LR, Reich RR, Dunn RL, Jiang DD, Gillis KA, Green E, Hajiran A, Hugar L, Zemp L, Zhang J, Jain RK, Chahoud J, Spiess PE, Manley BJ, Sexton WJ, Hollenbeck BK, Gilbert SM. Survival Outcomes Associated With Cytoreductive Nephrectomy in Patients With Metastatic Clear Cell Renal Cell Carcinoma. JAMA Netw Open. 2022 May.5(5):e2212347. Pubmedid: 35576003. Pmcid: PMC9112069.
      • Ionescu F, Zhang J, Wang L. Clinical Applications of Liquid Biopsy in Prostate Cancer: From Screening to Predictive Biomarker. Cancers (Basel). 2022 Mar.14(7). Pubmedid: 35406500. Pmcid: PMC8996910.
      • Chakiryan NH, Jiang DD, Gillis KA, Green E, Hajiran A, Hugar L, Zemp L, Zhang J, Jain R, Chahoud J, Li R, Sexton W, Manley BJ, Gilbert SM. Comparative effectiveness analysis of first-line immunotherapy versus chemotherapy in metastatic urothelial carcinoma of the bladder. Urol Oncol. 2022 Mar.40(3):107.e11-107.e17. Pubmedid: 34426068.
      • Chatzkel J, Schell MJ, Chahoud J, Zhang J, Jain R, Swank J, Ludlow S, Lombardi K, Lucas Y, Croft C, Rembisz J, Jameel G, Fishman M. Coordinated Pembrolizumab and High Dose IL-2 (5-in-a-Row Schedule) for Therapy of Metastatic Clear Cell Renal Cancer. Clin Genitourin Cancer. 2022 Jun.20(3):252-259. Pubmedid: 35249821.
      • Zhang J, Cunningham J, Brown J, Gatenby R. Evolution-based mathematical models significantly prolong response to abiraterone in metastatic castrate-resistant prostate cancer and identify strategies to further improve outcomes. Elife. 2022 Jun.11. Pubmedid: 35762577. Pmcid: PMC9239688.
      • Labadie BW, Morris DS, Bryce AH, Given R, Zhang J, Abida W, Chowdhury S, Patnaik A. Guidelines for Management of Treatment-Emergent Adverse Events During Rucaparib Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. Cancer Manag Res. 2022 Feb.14:673-686. Pubmedid: 35210863. Pmcid: PMC8860352.
      • Li R, Zhang J, Gilbert SM, Conejo-Garcia J, Mulé JJ. Using oncolytic viruses to ignite the tumour immune microenvironment in bladder cancer. Nat Rev Urol. 2021 Sep.18(9):543-555. Pubmedid: 34183833.
      • Chakiryan NH, Jiang DD, Gillis KA, Green E, Hajiran A, Hugar L, Zemp L, Zhang J, Jain R, Chahoud J, Poch M, Manley BJ, Li R, Sexton W, Gilbert SM. Pathological Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer. J Urol. 2021 Oct.206(4):924-932. Pubmedid: 34032503.
      • Bibok A, Mhaskar R, Jain R, Zhang J, Frakes J, Hoffe S, El-Haddad G, Parikh N, Ahmed A, Fishman MN, Choi J, Kis B. Role of Radioembolization in the Management of Liver-Dominant Metastatic Renal Cell Carcinoma: A Single-Center, Retrospective Study. Cardiovasc Intervent Radiol. 2021 Nov.44(11):1755-1762. Pubmedid: 34312688.
      • Chakiryan NH, Jiang DD, Gillis KA, Green E, Hajiran A, Hugar L, Zemp L, Zhang J, Jain RK, Chahoud J, Spiess PE, Sexton W, Gilbert SM, Manley BJ. Real-World Survival Outcomes Associated With First-Line Immunotherapy, Targeted Therapy, and Combination Therapy for Metastatic Clear Cell Renal Cell Carcinoma. JAMA Netw Open. 2021 May.4(5):e2111329. Pubmedid: 34032854. Pmcid: PMC8150693.
      • Rubino S, Kim Y, Zhou J, Dhillon J, Li R, Spiess P, Poch M, Manley BJ, Pow-Sang J, Gilbert S, Sexton W, Zhang J. Positive Ki-67 and PD-L1 expression in post-neoadjuvant chemotherapy muscle-invasive bladder cancer is associated with shorter overall survival: a retrospective study. World J Urol. 2021 May.39(5):1539-1547. Pubmedid: 32656671.
      • Mason NT, Burkett JM, Nelson RS, Pow-Sang JM, Gatenby RA, Kubal T, Peabody JW, Letson GD, McLeod HL, Zhang J. Budget Impact of Adaptive Abiraterone Therapy for Castration-Resistant Prostate Cancer. Am Health Drug Benefits. 2021 Mar.14(1):15-20. Pubmedid: 33841621. Pmcid: PMC8025923.
      • Yuan Z, Fernandez D, Dhillon J, Abraham-Miranda J, Awasthi S, Kim Y, Zhang J, Jain R, Serna A, Pow-Sang JM, Poch M, Li R, Manley B, Fink A, Naghavi A, Torres-Roca JF, Grass GD, Kim S, Latifi K, Hunt D, Johnstone PAS, Yamoah K. Proof-of-principle Phase I results of combining nivolumab with brachytherapy and external beam radiation therapy for Grade Group 5 prostate cancer: safety, feasibility, and exploratory analysis. Prostate Cancer P D. 2021 Mar.24(1):140-149. Pubmedid: 32651467. Pmcid: PMC7882397.
      • Zhang J, Cunningham JJ, Brown JS, Gatenby RA. Response to Mistry. Nat Commun. 2021 Jan.12(1):329. Pubmedid: 33436553. Pmcid: PMC7804311.
      • Loehr A, Patnaik A, Campbell D, Shapiro J, Bryce AH, McDermott R, Sautois B, Vogelzang NJ, Bambury RM, Voog E, Zhang J, Piulats JM, Hussain A, Ryan CJ, Merseburger AS, Daugaard G, Heidenreich A, Fizazi K, Higano CS, Krieger LE, Sternberg C, Watkins SP, Despain D, Simmons AD, Dowson M, Golsorkhi T, Chowdhury S, Abida W. Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study. Clin Cancer Res. 2021 Dec.27(24):6677-6686. Pubmedid: 34598946. Pmcid: PMC8678310.
      • Li R, Sundi D, Zhang J, Kim Y, Sylvester RJ, Spiess PE, Poch MA, Sexton WJ, Black PC, McKiernan JM, Steinberg GD, Kamat AM, Gilbert SM. Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin. Eur Urol. 2020 Sep.78(3):387-399. Pubmedid: 32143924. Pmcid: PMC7771323.
      • Jain RK, Skelton WP, Zhang J. Emerging Treatment Options for the Treatment of Metastatic Urothelial Cancer: Therapeutic Potential of Enfortumab Vedotin. Cancer Manag Res. 2020 Sep.12:8379-8386. Pubmedid: 32982431. Pmcid: PMC7494003.
      • Abida W, Patnaik A, Campbell D, Shapiro J, Bryce AH, McDermott R, Sautois B, Vogelzang NJ, Bambury RM, Voog E, Zhang J, Piulats JM, Ryan CJ, Merseburger AS, Daugaard G, Heidenreich A, Fizazi K, Higano CS, Krieger LE, Sternberg CN, Watkins SP, Despain D, Simmons AD, Loehr A, Dowson M, Golsorkhi T, Chowdhury S. Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration. J Clin Oncol. 2020 Nov.38(32):3763-3772. Pubmedid: 32795228. Pmcid: PMC7655021.
      • Abida W, Campbell D, Patnaik A, Shapiro JD, Sautois B, Vogelzang NJ, Voog EG, Bryce AH, McDermott R, Ricci F, Rowe J, Zhang J, Piulats JM, Fizazi K, Merseburger AS, Higano CS, Krieger LE, Ryan CJ, Feng FY, Simmons AD, Loehr A, Despain D, Dowson M, Green F, Watkins SP, Golsorkhi T, Chowdhury S. Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study. Clin Cancer Res. 2020 Jun.26(11):2487-2496. Pubmedid: 32086346. Pmcid: PMC8435354.
      • O'Donnell PH, Arkenau HT, Sridhar SS, Ong M, Drakaki A, Spira AI, Zhang J, Gordon MS, Degboe AN, Gupta AK, Mukhopadhyay P, Huang W, Abdullah SE, Angra N, Roskos LK, Guo X, Friedlander T. Patient-reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose-escalation study 1108. Cancer. 2020 Jan.126(2):432-443. Pubmedid: 31581306.
      • Brady-Nicholls R, Nagy JD, Gerke TA, Zhang T, Wang AZ, Zhang J, Gatenby RA, Enderling H. Prostate-specific antigen dynamics predict individual responses to intermittent androgen deprivation. Nat Commun. 2020 Apr.11(1):1750. Pubmedid: 32273504. Pmcid: PMC7145869.
      • West J, You L, Zhang J, Gatenby RA, Brown JS, Newton PK, Anderson ARA. Towards Multidrug Adaptive Therapy. Cancer Res. 2020 Apr.80(7):1578-1589. Pubmedid: 31948939. Pmcid: PMC7307613.
      • Rosenberg J, Sridhar SS, Zhang J, Smith D, Ruether D, Flaig TW, Baranda J, Lang J, Plimack ER, Sangha R, Heath EI, Merchan J, Quinn DI, Srinivas S, Milowsky M, Wu C, Gartner EM, Zuo P, Melhem-Bertrandt A, Petrylak DP. EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma. J Clin Oncol. 2020 Apr.38(10):1041-1049. Pubmedid: 32031899. Pmcid: PMC7106979.
      • Gatenby RA, Zhang J, Brown JS. First Strike-Second Strike Strategies in Metastatic Cancer: Lessons from the Evolutionary Dynamics of Extinction. Cancer Res. 2019 Jul.79(13):3174-3177. Pubmedid: 31221821. Pmcid: PMC6606376.
      • West JB, Dinh MN, Brown JS, Zhang J, Anderson AR, Gatenby RA. Multidrug Cancer Therapy in Metastatic Castrate-Resistant Prostate Cancer: An Evolution-Based Strategy. Clin Cancer Res. 2019 Jul.25(14):4413-4421. Pubmedid: 30992299. Pmcid: PMC6665681.
      • Yao J, Chen Y, Nguyen DT, Thompson ZJ, Eroshkin AM, Nerlakanti N, Patel AK, Agarwal N, Teer JK, Dhillon J, Coppola D, Zhang J, Perera R, Kim Y, Mahajan K. The Homeobox gene, HOXB13, Regulates a Mitotic Protein-Kinase Interaction Network in Metastatic Prostate Cancers. Sci Rep. 2019 Jul.9(1):9715. Pubmedid: 31273254. Pmcid: PMC6609629.
      • Chatzkel J, Mocha J, Smith J, Zhou JM, Kim Y, El-Haddad G, Zhang J. Circulating tumor cells and γH2AX as biomarkers for responsiveness to radium-223 in advanced prostate cancer patients. Future Sci OA. 2019 Dec.6(1):FSO437. Pubmedid: 31915536. Pmcid: PMC6920735.
      • Adashek JJ, Jain RK, Zhang J. Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer. Cells. 2019 Aug.8(8). Pubmedid: 31404966. Pmcid: PMC6721701.
      • Mei L, Zhang J, He K, Zhang J. Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand. J Hematol Oncol. 2019 Apr.12(1):43. Pubmedid: 31018854. Pmcid: PMC6482552.
      • Gupta S, Nordquist LT, Fleming MT, Berry WR, Zhang J, Ervin SL, Eisner JR, Baskin-Bey ES, Shore ND. Phase I Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer. Clin Cancer Res. 2018 Nov.24(21):5225-5232. Pubmedid: 30012563.
      • Peyton CC, Tang D, Reich RR, Azizi M, Chipollini J, Pow-Sang JM, Manley B, Spiess PE, Poch MA, Sexton WJ, Fishman M, Zhang J, Gilbert SM. Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder Cancer. JAMA Oncol. 2018 Nov.4(11):1535-1542. Pubmedid: 30178038. Pmcid: PMC6248089.
      • Poch M, Hall M, Joerger A, Kodumudi K, Beatty M, Innamarato PP, Bunch BL, Fishman MN, Zhang J, Sexton WJ, Pow-Sang JM, Gilbert SM, Spiess PE, Dhillon J, Kelley L, Mullinax J, Sarnaik AA, Pilon-Thomas S. Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer. Oncoimmunology. 2018 Jul.7(9):e1476816. Pubmedid: 30228944. Pmcid: PMC6140546.
      • Nerlakanti N, Yao J, Nguyen DT, Patel AK, Eroshkin AM, Lawrence HR, Ayaz M, Kuenzi BM, Agarwal N, Chen Y, Gunawan S, Karim RM, Berndt N, Puskas J, Magliocco AM, Coppola D, Dhillon J, Zhang J, Shymalagovindarajan S, Rix U, Kim Y, Perera R, Lawrence NJ, Schonbrunn E, Mahajan K. Targeting the BRD4-HOXB13 Coregulated Transcriptional Networks with Bromodomain-Kinase Inhibitors to Suppress Metastatic Castration-Resistant Prostate Cancer. Mol Cancer Ther. 2018 Dec.17(12):2796-2810. Pubmedid: 30242092. Pmcid: PMC6528782.
      • Powles T, O'Donnell PH, Massard C, Arkenau HT, Friedlander TW, Hoimes CJ, Lee JL, Ong M, Sridhar SS, Vogelzang NJ, Fishman MN, Zhang J, Srinivas S, Parikh J, Antal J, Jin X, Gupta AK, Ben Y, Hahn NM. Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study. JAMA Oncol. 2017 Sep.3(9):e172411. Pubmedid: 28817753. Pmcid: PMC5824288.
      • Zhang J, Cunningham JJ, Brown JS, Gatenby RA. Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer. Nat Commun. 2017 Nov.8(1):1816. Pubmedid: 29180633. Pmcid: PMC5703947.
      • You L, Brown JS, Thuijsman F, Cunningham JJ, Gatenby RA, Zhang J, Staňková K. Spatial vs. non-spatial eco-evolutionary dynamics in a tumor growth model. J Theor Biol. 2017 Dec.435:78-97. Pubmedid: 28870617.
      • Leone AR, Zargar-Shoshtari K, Diorio GJ, Sharma P, Boulware D, Gilbert SM, Powsang JM, Zhang J, Sexton WJ, Spiess PE, Poch MA. Neoadjuvant Chemotherapy in Elderly Patients With Bladder Cancer: Oncologic Outcomes From a Single Institution Experience. Clin Genitourin Cancer. 2017 Aug.15(4):e583-e589. Pubmedid: 28410909. Pmcid: PMC7771283.
      • Zargar-Shoshtari K, Kongnyuy M, Sharma P, Fishman MN, Gilbert SM, Poch MA, Pow-Sang JM, Spiess PE, Zhang J, Sexton WJ. Clinical role of additional adjuvant chemotherapy in patients with locally advanced urothelial carcinoma following neoadjuvant chemotherapy and cystectomy. World J Urol. 2016 Nov.34(11):1567-1573. Pubmedid: 27072536.
      • Wu M, Seto E, Zhang J. E2F1 enhances glycolysis through suppressing Sirt6 transcription in cancer cells. Oncotarget. 2015 May.6(13):11252-11263. Pubmedid: 25816777. Pmcid: PMC4484454.
      • Wu M, Dickinson SI, Wang X, Zhang J. Expression and function of SIRT6 in muscle invasive urothelial carcinoma of the bladder. Int J Clin Exp Pathol. 2014 Sep.7(10):6504-6513. Pubmedid: 25400728. Pmcid: PMC4230126.
      • Wu M, Wang X, McGregor N, Pienta K, Zhang J. Dynamic regulation of Rad51 by E2F1 and p53 in prostate cancer cells upon drug-induced DNA damage under hypoxia. Mol Pharmacol. 2014 Jun.85(6):866-876. Pubmedid: 24627085. Pmcid: PMC4014666.
      • Liu JJ, Zhang J. Sequencing systemic therapies in metastatic castration-resistant prostate cancer. Cancer Control. 2013 Jul.20(3):181-187. Pubmedid: 23811702.
      • Henderson-Jackson E, Sexton W, Zhang J, Hakam A, Petrovskyy VS, Bui MM, Chuang ST. Cystic prostatic ductal adenocarcinoma: an unusual presentation and cytological diagnosis. Ann Clin Lab Sci. 2012.42(1):81-88. Pubmedid: 22371914.
      • Zhang J, Lee J, Urba S, Foster J, Worden F. A phase II trial evaluating weekly docetaxel and capecitabine in patients with metastatic or advanced, locally recurrent head and neck cancers. Cancer Invest. 2010 Nov.28(9):910-916. Pubmedid: 20590443.
      • Kang HG, Jenabi JM, Zhang J, Keshelava N, Shimada H, May WA, Ng T, Reynolds CP, Triche TJ, Sorensen PH. E-cadherin cell-cell adhesion in ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase. Cancer Res. 2007 Apr.67(7):3094-3105. Pubmedid: 17409416. Pmcid: PMC3906735.
      • Hu-Lieskovan S, Zhang J, Wu L, Shimada H, Schofield DE, Triche TJ. EWS-FLI1 fusion protein up-regulates critical genes in neural crest development and is responsible for the observed phenotype of Ewing's family of tumors. Cancer Res. 2005 Jun.65(11):4633-4644. Pubmedid: 15930281.
      • Zhang J, Hu S, Schofield DE, Sorensen PH, Triche TJ. Selective usage of D-Type cyclins by Ewing's tumors and rhabdomyosarcomas. Cancer Res. 2004 Sep.64(17):6026-6034. Pubmedid: 15342383.
      • Tsao JL, Zhang J, Salovaara R, Li ZH, Järvinen HJ, Mecklin JP, Aaltonen LA, Shibata D. Tracing cell fates in human colorectal tumors from somatic microsatellite mutations: evidence of adenomas with stem cell architecture. Am J Pathol. 1998 Oct.153(4):1189-1200. Pubmedid: 9777950. Pmcid: PMC1853055.
      • Zhang J. Poly (ADP-ribose) polymerase inhibitor: an evolving paradigm in the treatment of prostate cancer. Asian J Androl. 16(3):401-406. Pubmedid: 24589464. Pmcid: PMC4023365.

    Find a Researcher Search